156 related articles for article (PubMed ID: 18351184)
1. Internal medicine, renal anaemia, and erythropoiesis-stimulating agents (ESAS).
Veys N; Van Biesen W; Lameire N
Acta Clin Belg; 2007; 62(6):396-407. PubMed ID: 18351184
[No Abstract] [Full Text] [Related]
2. Peginesatide: a potential erythropoiesis stimulating agent for the treatment of anemia of chronic renal failure.
Doss S; Schiller B
Nephrol Nurs J; 2010; 37(6):617-26. PubMed ID: 21290916
[TBL] [Abstract][Full Text] [Related]
3. [Role of renal anemia in progression of chronic kidney disease].
Racki S; Maleta I
Acta Med Croatica; 2009 Sep; 63 Suppl 1():33-7. PubMed ID: 20235353
[TBL] [Abstract][Full Text] [Related]
4. Erythropoiesis stimulating agents (ESAs) for congestive heart failure: the red and the black.
Robles NR; Macias JF; Herrera J
Eur J Intern Med; 2014 Feb; 25(2):193-6. PubMed ID: 24491240
[TBL] [Abstract][Full Text] [Related]
5. Erythropoiesis-stimulating agents in anemia: use and misuse.
Dharmarajan TS; Widjaja D
J Am Med Dir Assoc; 2009 Nov; 10(9):607-16. PubMed ID: 19883882
[TBL] [Abstract][Full Text] [Related]
6. [Current issues in erythropoietin therapy of renal anemia].
Zakar G
Lege Artis Med; 2007 Oct; 17(10):667-73. PubMed ID: 19227596
[TBL] [Abstract][Full Text] [Related]
7. Treating anemia with erythropoiesis-stimulating agents: effects on quality of life.
Moossavi S; Freedman BI
Arch Intern Med; 2009 Jun; 169(12):1100-1. PubMed ID: 19546408
[No Abstract] [Full Text] [Related]
8. Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease.
Carrero JJ; Bárány P; Yilmaz MI; Qureshi AR; Sonmez A; Heimbürger O; Ozgurtas T; Yenicesu M; Lindholm B; Stenvinkel P
Nephrol Dial Transplant; 2012 Feb; 27(2):709-15. PubMed ID: 21617198
[TBL] [Abstract][Full Text] [Related]
9. Erythropoiesis-stimulating agents for the management of anemia of chronic kidney disease: past advancements and current innovations.
Dutka P
Nephrol Nurs J; 2012; 39(6):447-57. PubMed ID: 23469411
[TBL] [Abstract][Full Text] [Related]
10. Choice of erythropoiesis stimulating agent in ESRD.
Fishbane S; Shah HH
Nephrol News Issues; 2013 Jun; 27(7):Supp 10-2. PubMed ID: 23855143
[No Abstract] [Full Text] [Related]
11. Correcting iron-restricted erythropoiesis and improving anemia in patients on hemodialysis: practical tips that can make a difference.
Easom A
Nephrol Nurs J; 2009; 36(5):529-37, 553. PubMed ID: 19856814
[TBL] [Abstract][Full Text] [Related]
12. Erythropoiesis stimulating agents and anaemia of end-stage renal disease.
Schmid H; Schiffl H
Cardiovasc Hematol Agents Med Chem; 2010 Jul; 8(3):164-72. PubMed ID: 20443766
[TBL] [Abstract][Full Text] [Related]
13. Erythropoiesis-stimulating agents in kidney and cardiac disease.
Fluck R
Br J Hosp Med (Lond); 2006 Oct; 67(10):533-7. PubMed ID: 17069130
[No Abstract] [Full Text] [Related]
14. Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure, part III.2: treatment of anaemia with iron.
Vaage-Nilsen O
Nephrol Dial Transplant; 2005 Jul; 20(7):1512-3; author reply 1513-4. PubMed ID: 15967789
[No Abstract] [Full Text] [Related]
15. Anemia management among hemodyalisis patients at the University Hospital in Puerto Rico.
Ocasio HE; Diaz H; Cangiano JL; Báez R; Suárez E
Bol Asoc Med P R; 2014; 106(2):9-12. PubMed ID: 25065044
[TBL] [Abstract][Full Text] [Related]
16. [How do we optimally evaluate iron stores in dialyzed patients treated with erythropoiesis stimulating agent?].
Kessler M; Salignac S; Aimone-Gastin I
Nephrol Ther; 2006 Sep; 2 Suppl 4():S261-5. PubMed ID: 17373268
[TBL] [Abstract][Full Text] [Related]
17. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?
Singh AK
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S5-13. PubMed ID: 19010260
[TBL] [Abstract][Full Text] [Related]
18. Anemia and cardiovascular risk in the patient with kidney disease.
Fishbane S
Heart Fail Clin; 2008 Oct; 4(4):401-10. PubMed ID: 18760752
[TBL] [Abstract][Full Text] [Related]
19. [Additional measures of treatment in patients with renal anemia].
Belavić Z; Kupres V
Acta Med Croatica; 2009 Sep; 63 Suppl 1():62-8. PubMed ID: 20232553
[TBL] [Abstract][Full Text] [Related]
20. Do pentoxifylline and ascorbic acid improve erythropoiesis stimulating agent resistance?
Rho M
Semin Dial; 2011; 24(4):378-9. PubMed ID: 21801213
[No Abstract] [Full Text] [Related]
[Next] [New Search]
